Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12947908 | 0.87 | DRD3 (0.63) | DRD3DRD2 | |
| SCHEMBL2081330 | 0.85 | DRD3 (1.00) | DRD3DRD2 | |
| SCHEMBL2080310 | 0.85 | DRD3 (1.00) | DRD3DRD2 | |
| SCHEMBL2080308 | 0.85 | DRD3 (1.00) | DRD3DRD2 | |
| SCHEMBL2936540 | 0.85 | DRD3 (0.71) | DRD3DRD2 | |
| SCHEMBL969088 | 0.85 | DRD3 (0.54) | DRD3 | |
| SCHEMBL323406 | 0.83 | DRD3 (1.00) | DRD3DRD2 | |
| SCHEMBL2078437 | 0.83 | DRD3 (1.00) | DRD3DRD2 | |
| SCHEMBL29389668 | 0.83 | DRD3 (1.00) | DRD3DRD2 | |
| SCHEMBL2080515 | 0.83 | DRD3 (1.00) | DRD3DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902188-B2 | Morpholine dopamine agonists | PFIZER INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902188-B2 | Morpholine dopamine agonists | PFIZER INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902188-B2 | Morpholine dopamine agonists | PFIZER INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-7871982-B2 | Lincomycin derivatives and antimicrobial agents comprising the same as active ingredient | MEIJI SEIKA KAISHA, LTD. (JP) | 2011-01-18 | — | — | US | disclosed |
| EP-1572214-B1 | MORPHOLINE DERIVATIVES FOR USE AS DOPAMINE AGONISTS IN THE TREATMENT OF I.A. SEXUAL DYSFUNCTION | PFIZER LTD (GB) | 2010-03-17 | — | — | EP | disclosed |
| EP-1572214-B1 | MORPHOLINE DERIVATIVES FOR USE AS DOPAMINE AGONISTS IN THE TREATMENT OF I.A. SEXUAL DYSFUNCTION | PFIZER LTD (GB) | 2010-03-17 | — | — | EP | disclosed |
| US-20090318451-A1 | MORPHOLINE DOPAMINE AGONISTS FOR THE TREATMENT OF PAIN | PFIZER INC. | 2009-12-24 | — | — | US | disclosed |
| US-20090318451-A1 | MORPHOLINE DOPAMINE AGONISTS FOR THE TREATMENT OF PAIN | PFIZER INC. | 2009-12-24 | — | — | US | disclosed |
| US-20090318451-A1 | MORPHOLINE DOPAMINE AGONISTS FOR THE TREATMENT OF PAIN | PFIZER INC. | 2009-12-24 | — | — | US | disclosed |
| US-20090270384-A1 | MORPHOLINE DOPAMINE AGONISTS | PFIZER INC | 2009-10-29 | — | — | US | disclosed |
| US-7323462-B2 | Morpholine dopamine agonists | PFIZER INC. (US) | 2008-01-29 | — | — | US | disclosed |
| US-7323462-B2 | Morpholine dopamine agonists | PFIZER INC. (US) | 2008-01-29 | — | — | US | disclosed |
| US-20060235016-A1 | Morpholine Dopamine Agonists | PFIZER INC | 2006-10-19 | — | — | US | disclosed |
| US-20060052435-A1 | Selective dopamin d3 receptor agonists for the treatment of sexual dysfunction | VAN DER GRAAF PIETER H | 2006-03-09 | — | — | US | disclosed |
| EP-1572214-A1 | MORPHOLINE DERIVATIVES FOR USE AS DOPAMINE AGONISTS IN THE TREATMENT OF I.A. SEXUAL DYSFUNCTION | Pfizer Limited (GB) | 2005-09-14 | — | — | EP | disclosed |
| US-20040259874-A1 | Morpholine dopamine agonists | PFIZER INC. | 2004-12-23 | — | — | US | disclosed |
| EP-1463508-A1 | SELECTIVE DOPAMINE D3 RECEPTOR AGONISTS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | Pfizer Limited (GB) | 2004-10-06 | — | — | EP | disclosed |
| WO-2004052372-A1 | MORPHOLINE DERIVATIVES FOR USE AS DOPAMINE AGONISTS IN THE TREATMENT OF I.A. SEXUAL DYSFUNCTION | PFIZER LIMITED (GB) | 2004-06-24 | — | — | WO | disclosed |
| WO-2003051370-A1 | SELECTIVE DOPAMINE D3 RECEPTOR AGONISTS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER LIMITED (GB) | 2003-06-26 | — | — | WO | disclosed |
| WO-2003051370-A1 | SELECTIVE DOPAMINE D3 RECEPTOR AGONISTS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER LIMITED (GB) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235016-A1 | Morpholine Dopamine Agonists | DBH, OPRM1, ADRA2B | DRD3 19/4885DRD2 9/4885 |
| US-20040259874-A1 | Morpholine dopamine agonists | DBH, OPRM1, OPRD1 | DRD3 35/4885DRD2 16/4885 |
| US-20090270384-A1 | MORPHOLINE DOPAMINE AGONISTS | DBH, OPRM1, CHRM1 | DRD3 19/4885DRD2 10/4885 |
| US-20090318451-A1 | MORPHOLINE DOPAMINE AGONISTS FOR THE TREATMENT OF PAIN | OPRL1, OPRD1, OPRK1 | DRD3 26/4885DRD2 13/4885 |
| US-20060052435-A1 | Selective dopamin d3 receptor agonists for the treatment of sexual dysfunction | DRD3, ADRB3, DRD2 | DRD3 1/4885DRD2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.